2025-523677-41-00已完成1 期
(21174) Relative bioavailability study to investigate the pharmacokinetics of a single oral dose of asundexian administered as 50 mg pediatric formulation in comparison to 50 mg tablet (adult formulation) in fasted state and to investigate the effect of a high-fat, high-calorie meal on the 50 mg pediatric formulation in healthy adult participants
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Bayer AG
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Cmax, AUC and AUC(0-tlast) for asundexian after a single oral dose of 50 mg pediatric formulation compared to the 50 mg tablet in the fasted state
研究概览
简要总结
To investigate the pharmacokinetics of asundexian after a single oral dose of 50 mg pediatric formulation compared to the 50 mg tablet in the fasted state and to investigate the effect of a high-fat, high-calorie meal on the pharmacokinetics of the 50 mg asundexian pediatric formulation relative to fasted state
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent.
- •Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, ECG, and vital signs
- •BMI within the range 18 to 29.9 kg/m2 (both inclusive) at the screening.
- •Male or female participants
- •Contraceptive use by participant or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
排除标准
- •Pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study intervention(s) will not be normal.
- •Intake of specified food or beverages containing grapefruit, pomelo, tangelo, Seville oranges within 2 weeks before first study intervention administration.
- •Intake of quinine containing beverages like tonic water etc. within 2 weeks before first study intervention administration.
- •Findings in the ECG such as a clinically relevant second- degree AV block (if clinically relevant) or third-degree AV block, prolongation of the QRS complex equal or over 120 msec or of the QTc-interval corrected according to Fridericia’s (QTcF) formula over 450 msec identified in a standard 12-lead ECG at screening and upon confirmation of eligibility
- •Systolic blood pressure below 90 mmHg or above 140 mmHg at screening and upon confirmation of eligibility
- •Diastolic blood pressure below 60 mmHg or above 90 mmHg at screening and upon confirmation of eligibility
- •Known hypersensitivity to or intolerance of any study intervention (active substances or excipients of the preparations) to be used in the study – including e.g. non-investigational medicinal products, challenge agents, or rescue medication.
- •Known severe allergies, e.g., allergies to more than 3 allergens, allergies affecting the lower respiratory tract – allergic asthma, allergies requiring therapy with corticosteroids, urticaria or significant non-allergic drug reactions.
- •Febrile illness within 4 weeks before the start of the first study intervention.
- •Known coagulation disorders (e.g., von Willebrand’s disease, hemophilia).
- •Known disorders with increased bleeding risk (e.g., periodontosis, symptomatic hemorrhoids, acute gastritis, peptic ulcer etc.).
- •Known sensitivity to common causes of bleeding (e.g., nasal etc.), heavy menstrual periods in female participants.
- •Known or suspected liver disorders (e.g. Morbus Gilbert/ Meulengracht) and bile secretion/flow (cholestasis, also history of it).
- •Regular use of prescription drugs, over-the-counter drugs, supplements (e.g., carnitine products, high dose vitamins, anabolics) or herbal products (e.g., St. John’s wort) with the exception of medication used for contraception or hormonal replacement therapy within 14 days prior to the first administration of study intervention.
研究组 & 干预措施
BAY 2433334, Asundexian Bayer 10mg Granules
Test
干预措施: Asundexian Bayer 10mg Granules (Drug)
BAY 2433334, Asundexian Bayer 10mg Granules
Test
干预措施: BAY 2433334 (Drug)
结局指标
主要结局
Cmax, AUC and AUC(0-tlast) for asundexian after a single oral dose of 50 mg pediatric formulation compared to the 50 mg tablet in the fasted state
Cmax, AUC and AUC(0-tlast) for asundexian after a single oral dose of 50 mg pediatric formulation compared to the 50 mg tablet in the fasted state
Cmax, AUC and AUC(0-tlast) for asundexian after a single oral dose of 50 mg pediatric formulation after a high-fat meal relative to the fasted state
Cmax, AUC and AUC(0-tlast) for asundexian after a single oral dose of 50 mg pediatric formulation after a high-fat meal relative to the fasted state
次要结局
- Number of participants who experienced serious and non-serious TEAEs after administration of 50 mg asundexian as pediatric formulation and as table in the fasted state
- Number of participants who experienced serious and non-serious TEAEs after administration of 50 mg asundexian as pediatric formulation in the fed state
研究者
Therapeutic Area Head
Scientific
Bayer AG
研究点 (1)
Loading locations...
相似试验
尚未招募
3 期
An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12-month Treatment with Migalastat in Pediatric Subjects (aged 2 to < 12 years) with Fabry Disease and Amenable GLA VariantsFabry disease2025-521244-38-00Amicus Therapeutics Inc.1
招募中
3 期
Donidalorsen Treatment in Children with Hereditary Angioedema2025-523499-22-00Ionis Pharmaceuticals Inc.4
招募中
1 期
A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy SubjectsCardiomyopathyNCT07272330Shandong Suncadia Medicine Co., Ltd.38
招募中
不适用
A Double Blind Balanced Randomized Single Dose Two Treatment Two Sequence Two Period Two Way Crossover Oral Bioavailability Study Comparing Curcumin 1000 mg Hard CapsuleCTRI/2024/11/077316Cocrystal Health Industry Zhejiang Co Ltd12
尚未招募
1 期
PK and Relative Bioavailability of Novel Liquid Metformin vs TabletsNCT07300020Aspargo Labs, Inc24